Skip to main content
Erschienen in: Investigational New Drugs 4/2012

01.08.2012 | PRECLINICAL STUDIES

Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor

verfasst von: Lih-Ching Hsu, David E. Durrant, Ching-Chun Huang, Nai-Wen Chi, Riccardo Baruchello, Riccardo Rondanin, Cinzia Rullo, Paolo Marchetti, Giuseppina Grisolia, Daniele Simoni, Ray M. Lee

Erschienen in: Investigational New Drugs | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Summary

Hemiasterlins are cytotoxic tripeptides with antimicrotubule activity originally isolated from marine sponges. We have developed new hemiasterlin derivatives BF65 and BF78 that are highly potent to induce cancer cell death in the low nanomolar range. Examination of their mechanisms of cell cycle arrest and disruption of microtubules revealed an unusual characteristic in addition to anti-tubulin effect. Immunofluorescence staining revealed that A549 lung carcinoma cells treated with BF65 or BF78 exhibited both monopolar and multipolar mitotic spindles. Centrosomes were separated with short spindle microtubules in cells with multipolar spindles. In vitro tubulin polymerization assay confirmed that both BF65 and BF78 were highly potent to inhibit tubulin polymerization. These two compounds induced the formation of monoastral spindles suggesting that they might be inhibitors of mitotic kinesins such as KSP/Eg5. However, kinetic measurement of microtubule activated kinesin ATPase activity demonstrated that unlike the positive control monastrol, neither BF65 nor BF78 suppressed KSP/Eg5 activity. Hence the effect may be a variant form of tubulin inhibition. Similar to vinca alkaloids, BF compounds synergized with a colchicine site microtubule inhibitor stilbene 5c both in vitro and in vivo, which may provide a potential drug combination in the future clinical application.
Literatur
3.
Zurück zum Zitat Stevenson JP, Rosen M, Sun W et al (2003) Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21:4428–4438. doi:10.1200/JCO.2003.12.986 CrossRefPubMed Stevenson JP, Rosen M, Sun W et al (2003) Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21:4428–4438. doi:10.​1200/​JCO.​2003.​12.​986 CrossRefPubMed
7.
Zurück zum Zitat Blakey DC, Westwood FR, Walker M et al (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8:1974–1983PubMed Blakey DC, Westwood FR, Walker M et al (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8:1974–1983PubMed
8.
9.
Zurück zum Zitat Nabha SM, Mohammad RM, Dandashi MH et al (2002) Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly (ADP-ribose) polymerase cleavage. Clin Cancer Res 8:2735–2741PubMed Nabha SM, Mohammad RM, Dandashi MH et al (2002) Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly (ADP-ribose) polymerase cleavage. Clin Cancer Res 8:2735–2741PubMed
16.
Zurück zum Zitat McInnes C, Mezna M, Fischer PM (2005) Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem 5:181–197CrossRefPubMed McInnes C, Mezna M, Fischer PM (2005) Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem 5:181–197CrossRefPubMed
19.
Zurück zum Zitat Lee CW, Bélanger K, Rao SC et al (2008) A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 26:249–255. doi:10.1007/s10637-007-9097-9 CrossRefPubMed Lee CW, Bélanger K, Rao SC et al (2008) A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 26:249–255. doi:10.​1007/​s10637-007-9097-9 CrossRefPubMed
22.
Zurück zum Zitat Cao TM, Durrant D, Tripathi A et al (2008) Stilbene derivatives that are colchicine site microtubule inhibitors have anti-leukemic activity and minimal systemic toxicity. Am J Hematol 83:390–397. doi:10.1002/ajh.21104 CrossRefPubMed Cao TM, Durrant D, Tripathi A et al (2008) Stilbene derivatives that are colchicine site microtubule inhibitors have anti-leukemic activity and minimal systemic toxicity. Am J Hematol 83:390–397. doi:10.​1002/​ajh.​21104 CrossRefPubMed
23.
Zurück zum Zitat Bai R, Durso NA, Sackett DL, Hamel E (1999) Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1. Biochemistry 38:14302–14310. doi:10.1021/bi991323e CrossRefPubMed Bai R, Durso NA, Sackett DL, Hamel E (1999) Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1. Biochemistry 38:14302–14310. doi:10.​1021/​bi991323e CrossRefPubMed
24.
Zurück zum Zitat Loganzo F, Discafani CM, Annable T et al (2003) HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res 63:1838–1845PubMed Loganzo F, Discafani CM, Annable T et al (2003) HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res 63:1838–1845PubMed
29.
Zurück zum Zitat Durrant D, Richard J, Tripathi A et al (2009) Development of water soluble derivatives of cis-3, 4′, 5-trimethoxy-3′-aminostilbene for optimization and use in cancer therapy. Invest New Drugs 27:41–52. doi:10.1007/s10637-008-9139-y CrossRefPubMed Durrant D, Richard J, Tripathi A et al (2009) Development of water soluble derivatives of cis-3, 4′, 5-trimethoxy-3′-aminostilbene for optimization and use in cancer therapy. Invest New Drugs 27:41–52. doi:10.​1007/​s10637-008-9139-y CrossRefPubMed
30.
Zurück zum Zitat Webb MR (1992) A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems. Proc Natl Acad Sci U S A 89:4884–4887CrossRefPubMed Webb MR (1992) A continuous spectrophotometric assay for inorganic phosphate and for measuring phosphate release kinetics in biological systems. Proc Natl Acad Sci U S A 89:4884–4887CrossRefPubMed
31.
Zurück zum Zitat Wang LG, Liu XM, Kreis W, Budman DR (1999) The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44:355–361CrossRefPubMed Wang LG, Liu XM, Kreis W, Budman DR (1999) The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44:355–361CrossRefPubMed
32.
Zurück zum Zitat Millar JB, McGowan CH, Lenaers G, Jones R, Russell P (1991) p80cdc25 mitotic inducer is the tyrosine phosphatase that activates p34cdc2 kinase in fission yeast. EMBO J 10:4301–4309PubMed Millar JB, McGowan CH, Lenaers G, Jones R, Russell P (1991) p80cdc25 mitotic inducer is the tyrosine phosphatase that activates p34cdc2 kinase in fission yeast. EMBO J 10:4301–4309PubMed
33.
Zurück zum Zitat Lopez-Girona A, Furnari B, Mondesert O, Russell P (1999) Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature 397:172–175. doi:10.1038/16488 CrossRefPubMed Lopez-Girona A, Furnari B, Mondesert O, Russell P (1999) Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature 397:172–175. doi:10.​1038/​16488 CrossRefPubMed
36.
37.
Metadaten
Titel
Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor
verfasst von
Lih-Ching Hsu
David E. Durrant
Ching-Chun Huang
Nai-Wen Chi
Riccardo Baruchello
Riccardo Rondanin
Cinzia Rullo
Paolo Marchetti
Giuseppina Grisolia
Daniele Simoni
Ray M. Lee
Publikationsdatum
01.08.2012
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 4/2012
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-011-9702-9

Weitere Artikel der Ausgabe 4/2012

Investigational New Drugs 4/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.